Remove Communication Remove Download Remove Insurance Coverage and Processing
article thumbnail

RFK Jr looks to alter rare disease regulation by fast-tracking drug approvals

Pharmaceutical Technology

The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. RFK Jr did not question their importance, and acknowledged panellists’ calls for faster regulatory processes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

article thumbnail

Bridging the gap: A comprehensive approach to social determinants of health

Pharmaceutical Technology

Download the free report today for data-driven insights into RWD. Please check your inbox to download the Report. Better insights into how SDoH affects health can highlight the systemic influences that leave certain groups with worse health outcomes than others, despite similar health insurance coverage or access.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Harbour BioMed partners Otsuka on new T-cell therapy

Pharmaceutical Technology

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. We may still continue to send you service-related and other non-promotional communications. Topic sponsors are not involved in the creation of editorial content.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. Medicare Part A, Part B, and Part D do not generally cover approved weight loss medications like Saxenda, but Medicare Advantage plans may allow for expanded coverage, as per the Medicare.org site. By GlobalData. United Kingdom.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. Medicare Part A, Part B, and Part D do not generally cover approved weight loss medications like Saxenda, but Medicare Advantage plans may allow for expanded coverage, as per the Medicare.org site. By GlobalData. United Kingdom.

article thumbnail

SpliceBio secures $135m for gene therapy development

Pharmaceutical Technology

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. We may still continue to send you service-related and other non-promotional communications. Topic sponsors are not involved in the creation of editorial content.

article thumbnail

Release of International Book: “DTx An Opportunity for Italy and Beyond”

pharmaphorum

Unlike the abundance of freely downloadable wellbeing apps, DTx products are meant to be prescribed for a therapeutic indication and potentially eligible for reimbursement by national health services subject to health technology assessment studies. Contact: Antonietta Pannella, Marketing & Communications Director, Healthware Group.